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SUMMARY
We reviewed the long-term survival, treatment-related mortality and morbidity ofa continuous
cohort of patients with Hodgkin's disease diagnosed and staged at the Haematology unit ofthe
BelfastCityHospitalbetweenJanuary1973andOctober1992.Theanalysisincludedacomparison
of the survival of those patients who were entered into BNLI (British National Lymphoma
Investigation) trials compared to those not entered during this 20 year period. In addition
univariate and multivariate analysis ofprognostic factors was performed.
The complete remission rate (CR) was 79.6% with a 15 year survival of55.3%. On multivariate
analysis in which deaths due to active Hodgkin's disease only were considered age >50 emerged
as the most significant prognostic factor (P<0.0007), the presence of B symptoms also having
independent significance (P=0.008). Trial status did not have any independent prognostic
significance. Eighty one deaths occurred: active Hodgkin's disease (50), second malignancy (9),
treatment-related (10), unrelated (9), unknown (3).
This long-term follow up study provides useful information additional to the data produced by
clinical trials which are biased by selection criteria. The occurrence ofHaemophilus Influenzae
meningitis in a patient 17 years following splenectomy highlights the need for appropriate
vaccination ofpatients splenectomised for Hodgkin's disease.
INTRODUCTION
It is now 166 years since Thomas Hodgkin
published his original article "On some morbid
appearancesoftheabsorbentglandsandspleen",
in which he described six cases of a condition
which he believed to be a specific disease entity.
Within the last century Hodgkin's disease has
emerged as a curable malignancy due to the
efficacy of megavoltage radiotherapy,
combination chemotherapy, and more recently
marrowablativechemotherapy followedby stem
cell grafting. The survival of patients today has
dramatically improved when compared withthat
of untreated patients, whose five-year survival
was reported to be 5.6%.1 With the advent of
kilovoltage radiotherapy in the 1920's this figure
rose to 51%,2 and a further significant survival
increment (73.3% at 5 yrs) resulted from the use
of megavoltage radiotherapy in the 1950's.3
Within the last 3 decades the use ofcombination
chemotherapy and combined modality therapy
has improved survival with approximately 85%
ofpatients alive at five years.
Such survival data is mainly obtained from the
results of clinical trials, which are designed to
evaluatedifferenttherapeuticregimensinstrictly
equalpatientcohorts, aprocesswhichnecessitates
the use of inclusion/exclusion criteria. This
inherent selection process means that clinical
trials cannot assess the real survival probability
of all patients with a specific disease. For this
reason single centre outcome studies are an
important means of determining survival
outcomes in unselected cohorts ofpatients. This
study was undertaken primarily to ascertain the
long-term survival of all patients suffering from
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Hodgkin'sdiseasewhowerediagnosedandstaged
at the Belfast City Hospital over a twenty year
period. Secondary objectives were to compare
the survival ofthose patients entered into BNLI
trials withthosepatients who forvarious reasons
werenot,toassessthedelayedeffectsoftreatment
to identify the various causes of death and to
investigatethosefactorswhichadverselyaffected
survival in this continuous cohort of unselected
patients.
METHODS
We reviewed the case notes of 209 consecutive
patients with previously untreated Hodgkin's
disease who were diagnosed/staged in the
Haematology unit of the Belfast City Hospital
fromJanuary 1973 toOctober 1992. Onehundred
andtwelve ofthesepatientshadbeenenteredinto
various BNLI trials, following acceptance ofthe
histological diagnosis by the BNLI panel.
Pathology review
Limited resources prohibitedhistological review
ofallthe89non-trialpatient'sdiagnosticbiopsies,
but a local panel of pathologists was formed to
review the original histology of any of the non-
trialpatients in situations known to be associated
with diagnostic difficulty (i.e. original diagnosis
had been made on extranodal tissue, original
histology had not been classified using the Rye
classification, a second biopsy had questioned
the original diagnosis, a second malignancy had
been diagnosed simultaneously (within 6
months).) These criteria identified 18 cases for
review and with the additional aid of
immunocytochemistry a diagnosis of non
Hodgkin'slymphomawasfavouredinfourcases,
myeloproliferative disorder in two, and non-
diagnostic in two, leaving atotal of201 cases for
analysis.
Patients
The characteristics of the patient population
(N=201) which includes two sets of siblings are
shown in Table I. The median age was 32 (range
9 to 81), withtheusualmalepreponderance being
noted.
Staging method
PatientshadbeenstagedinaccordancewithBNLI
protocols. Routine staging investigations
included: FBCwithDWCC,baselineESR, serum
copper, lactatedehydrogenase, liverfunctiontests,
bone marrow examination and chest xray with or
without tomography. Prior to 1981 lymphangio-
TABLE I
Patientpopulation (N=201)
Variable Catrgory number %
Sex male 125 62
female 76 38
Age <50 152 75.6
>50 49 24.4
Trial status yes 112 55.7
no 89 44.3
B symptoms yes 119 59.2
no 82 40.8
Stage I 38 19
(Ann Arbor) II 69 34
III 58 29
IV 36 18
Histology LP 15 7
NS 130 65
MC 40 20
LD 12 6
U 4 2
Laparotomy yes 75 37
status no 126 63
Lymphangiography yes 61 30.3
no 140 69.7
LP=Lymphocyte predominant
NS=Nodular sclerosis
MC=Mixed cellularity
LD=Lymphocyte depleted
U=Unclassified
graphy with or without abdominal ultrasound
was used to detect infradiaphragmatic disease,
and following these investigations patients with
apparently localized disease and absence of B
symptoms(fever,nightsweatsand/orunexplained
loss of 10% of body weight) who would have
been suitable candidates for local radiotherapy
routinely underwent staging laparotomy with
splenectomy, wedge liver biopsy, and biopsy of
suspect abdominal glands. Since then the
increasing use of CT scanning of the thorax,
abdomen and pelvis effectively made
lymphangiography and laparotomy redundant4
as itbecameclearthatstaginglaparotomyhadno
impact on survival owing to the effectiveness of
salvagechemotherapyforpatientsrelapsing after
initial radiotherapy.
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Patient treatment
The patients entered into the BNLI trials were
treated according to trial protocols. Localized
disease was treated with either local or regional
radiotherapy of the mantle (MR) or inverted Y
type, and some patients with stage III disease
received total nodal irradiation (TNI). More
advanced stage disease was treated with
combination chemotherapy regimens: mustine,
vincristine,procarbazineandprednisone(MOPP);
chlorambucil, vincristine, procarbazine and
prednisone (LOPP); ordoxorubicin, vinblastine,
etoposide and prednisone (EVAP).5 6 In more
recent years the intensive regimen consisting of
carmustine, etoposide, cytarabine andmelphalan
(BEAM) followed by autologous stem cell
transplantationhasbeenused.7Elevenpatientsin
this cohort have undergone autologous
transplantation using bone marrow orperipheral
blood stem cells.
Theremainingpatientswhowerenotenteredinto
BNLI trials were treated in a similar fashion -
radiotherapy for localized disease without B
symptoms, and combination chemotherapy
regimens similar to the above.
Twenty four patients following initial staging
weretreatedandfollowedupattwoothercentres:
The Northern Ireland Centre for Clinical
Oncology and Radiotherapy (22 patients), and
Craigavon Area Hospital (two patients).
Response to treatment andpatientfollow-up
The clinical notes were studied to reassess the
responsetotreatmentatthecompletionoftherapy.
Criteria for complete remission (CR) were
disappearance of all clinical, biochemical and
radiological evidence of disease, and if CR
occurred it was dated from the completion of
therapy. Rates of relapse and subsequent
attainmentofsecond,third, andfourthremissions
were recorded. Complications of the disease or
its treatment such as sepsis, infertility, second
malignancy,herpeszoster,cardiacandrespiratory
sequelae were documented.
Follow-up information on all patients was
obtainedbytelephoning the generalpractitioner,
or by means of a written questionnaire.
Information on patients no longer living in
Northern Ireland was sought from the
haematology-oncology centre responsible for
patient care. Death certificates and post-mortem
reports were studied, and causes of death were
categorized as Hodgkin's disease-related,
treatment-related, second malignancy, other
causes , or unknown. In 200/201 cases overall
survival was measured from the date of
histological diagnosis to the date of death or to
September 1st, 1993 (date of study commence-
ment), with one patient being lost to follow-up
after 6 years of observation.
Statistical Analysis
Statistical analysis was carried out using SPSS
software. Survival was calculated using the life
tablemethodofKaplanandMeier. Intheanalysis
of prognostic factors deaths due to active
Hodgkin'sdiseaseonlywereincluded. Unrelated
and second malignancy deaths were disregarded
as were early deaths during induction
chemotherapy, most of which were due to
chemotherapy-induced sepsis. Comparisons in
univariate analysis wereperformed using the log
rank test. Factors which reached significance on
univariateanalysiswereanalysedusingastepwise
Cox proportional hazards regression. A final
modelwasobtainedcontainingonlythosefactors
which maintained independent prognostic
significance.
RESULTS
Response to treatment
TheCRratewas79.6%(160/201)andthemajority
ofthese patients (111) did not relapse. Ofthe 49
patients (31%) who relapsed approximately half
went on to achieve second CR(25/49). Second
relapse occurred in nine of these 25 patients
(36%), five ofwhom successfully achieved third
CR, andonepatientachievedfourthCR. Patients
who achieved CR were significantly younger
than non-remitters (P<0.001).
The majority of first relapses (45/49) occurred
within five years of the completion of therapy,
with only one relapse beyond 10 years and
remainder between 5-10 years.
Survival
Theoverall survivalforthe201 patients is shown
(Fig. 1) which includes deaths from all causes.
The 10 and 15 year survival rates were 61.3%
(confidence interval 54 to 68.6) and 55.3%
(confidence interval 47.2 to 63.4). The median
periodoffollow-up was 7.4years forallpatients,
and 11.6 years for those patients still alive.
Survival for patients who achieved CR was
significantlybetterthannonremitters (P<0.0001).
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Fig 1. Survival of all patients (N=201), with a
comparison ofthe survival ofpatients achieving
remission (remitters N=160) with that of non-
remitters (N=41), P<0.0001.
Figure 2 shows that the survival oftrial patients
fromBelfastisvery similartothatoftrialpatients
from other UK centres (G Vaughan Hudson,
personal communication).
Causes ofdeath
Eightyonedeathsoccurred,themajorityofwhich
(n=50) were due to active Hodgkin's disease.
Tendeaths weretreatment-related, includingtwo
splenectomy-related deaths: one early death due
to subphrenic abscess and haemorrhage from
multiple acute gastric ulcers; and one death due
to Haemophilus influenzae meningitis occurring
17 years following splenectomy in a stage IA
patient. Infection was amajorcontributingfactor
in the remaining treatment-related deaths with
several deaths from gram-negative sepsis, and
onedeathfromherpessimplexencephalitis. Nine
patients died from unrelated causes: trauma 3,
myocardial infarction 3 (2 in CR, 1 prior to
treatment), pulmonary embolism 1, stroke 1,
bronchopneumonia in CR 1. In three cases the
causeofdeathcouldnotbeaccuratelydetermined.
Second malignancy developing between 0.3-18
yrs (median 4 years) resulted in the death ofnine
patients (respiratory 4, gastro-intestinal 3,
lymphoblastic lymphoma 1, undetermined 1).
Other complications ofthe disease or its treatment
VIRAL INFECTIONS
Herpes zoster infection occurred in 41 patients
(21%) during the period of hospital follow-up,
andthreeofthesepatientshaddisseminatedzoster.
As previously mentioned a fatal case of herpes
simplex encephalitis occurred.
FERTILITY STATUS
Infertility post chemotherapy/radiotherapy was
only documented in eight patients, four male (3
ofwhom had received MOPP or LOPP, and one
who had received TNI + LOPP), and fourfemale
(one having receivedLOPP andEVAP, oneTNI,
and the remaining 2 patients BEAM
chemotherapy. In contrast 8 female patients who
received combination chemotherapy have
subsequently become pregnant.
Analysis ofprognosticfactors influencing survival
UNIVARIATE
The results of univariate analysis are shown in
Table II. Age >50 (P<0.0001), elevation of the
baseline ESR >50 mm/hr (P=0.0001), and
elevationofthebaselineserumcopper(P=0.0009)
emerged as the most significant factors
influencing survival. There was a trend towards
improved survival forpatients entered into trials
but this did not reach statistical significance
(P=0.08). In this analysis the following factors
were found not to be significant: sex, absolute
lymphocyte count <1.5 x109/L, elevation of the
serum LDH, mediastinal involvement,
histological subtype, and treatment period 1973-
1981 vs 1982- 1992.
Multivariate
Two factors alone age >50 and the presence ofB
symptoms maintained independent prognostic
significance (Table II). Elevation ofthe baseline
serumcopperapproachedsignificance(P=0.056).
Oversll survival ofpatiertswith Hodgkin's Disease entered
IntoBNU Trials from Belfast and all othercentres (1973.95)
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Fig 2. Survival of Belfast trial patients compared to
trial patients from other BNLI centres.
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TABLE II
Analysis ofprognosticfactors influencing survival
Univariate Multivariate
Significance (P) Significance (P) relative 95% CI
risk
Factor category numbers
Age <=50 152
>50 49 <0.0001 0.007 2.73 (1.31-5.7)
B symptoms no 82
yes 119 <0.0001 0.008 3.79 (1.4-10.2)
Copper <=26.7 71
>26.7 81 0.0009 0.056 2.33 (0.97-5.58)
ESR <=50 102
>50 74 0.0001
Trial status yes 112
no 89 0.08
Albumin >=35 98
<35 47 0.0147
Alkaline <=280 74
phosphatase >280 71 0.02
Bone marrow no 163
involvement yes 19 0.003
Stage 4 no 165
yes 36 0.0007
Hb<10 no 165
yes 23 0.0042
Platelets 150-400 118
>400 59 0.096
Analysis includes only deaths due to active Hodgkin's disease (N=50)
Comparison ofthetrialpatientswiththenon- trialpatients
Trialpatients wereasignificantlyyoungercohort
(P=0.028). Univariate analysis showed a trend
towards longer survival in the trial patients but
this did not reach statistical significance.
DISCUSSION
Long term follow-up studies in curable
malignancies are essential to enable clinicians to
assess treatment-related morbidity and mortality
and subsequently modify treatment protocols in
order to minimize unwanted sequelae, without
jeopardizing the prospect of cure. The survival
data from studies such as this provide a full
assessment of the efficacy of treatment and the
morbid consequences of it, and are a source of
valuable information which can be subjected to
meta- analysis. Oursurvivalratesareverysimilar
to the results of the relatively few centres that
have investigated long term survival in a
consecutive group of patients,8'-0 to the figures
produced by the international data base on
Hodgkin's disease," and to the BNLI data for
other trial centres (Vaughan Hudson G, personal
communication). An improved outcome for
patientsmanagedincomprehensivecancercentres
rather than in general hospitals has been
recorded.'2 Our data suggests that the benefit of
trialparticipationisnotrestrictedtothosepatients
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randomized into clinical trials but that it reaches
the nontrial cohort in the participating centre, a
finding noted inthe management ofpatients with
myeloma in Finland.13
The knowledge of important prognostic factors
has significantly modified the staging and
treatment of Hodgkin's disease in the past two
decades. Advanced age is commonly found to be
ahighlysignificantadversefactoronmultivariate
analysis,5 6, 8-11 as is the occurrence of B
symptoms.'1,4 In our method of analysis of
prognostic factors we have disregarded not only
unrelated and second malignancy deaths but also
early induction deaths, the majority of which
were due to chemotherapy-induced sepsis,
believing such deaths to relate to random
unpredictableeventspossiblyrelatedtovariability
ofmarrowdepressionsecondarytochemotherapy
and/or variability in depression of cellular
immunity. When this method of analysis is
applied, only the factors ofadvanced age and the
presence of B symptoms maintain independent
significance, with elevation ofthe serum copper
approaching significance.
Elevation of the serum copper in Hodgkin's
disease was first described in 1957,15 and since
then it has been infrequently mentioned in the
literature.16-20 Inthis study elevation ofthe serum
copper approached significance on multivariate
analysis We feel that further evaluation of the
prognostic significance ofthisvariableinalarger
number ofpatients would be interesting in order
to clarify its status as an independent prognostic
factor.
Active Hodgkin's disease caused the majority of
deaths 50/81 (64%) in this series, and this
correlates closely with data from previously
published series,8 and with data produced from
theinternationaldatabaseonHodgkin'sdisease" I
inwhich 14,225 patients wereregistered. Nine of
ourpatientsdeveloped secondmalignancy(4.5%)
whichis similartothefindings ofotherauthors,8 2123
and the latter three authors have calculated that
up to a 6 fold excess risk of all second cancers
exists in patients treated for Hodgkin's disease
when compared to general population incidence
data. Advanced age at the time of diagnosis has
been associated with an increased incidence of
secondmalicy 11,22,23 ndcombinedmodality
therapy has also been implicated.22' 24 The
occurrence of acute myeloid leukaemia has been
reported between 0.4%o-lO % ofpatients,8'24 yet
nocaseshavebeenseeninthis seriestodate. This
may be due to the low use of MOPP therapy in
this cohort, as MOPP therapy alone or in
combination with radiotherapy has been shown
to be a significant predisposing factor.
Two laparotomy-related deaths occurred in this
series, one of which was due to Haemophilus
influenzae meningitis occurring 17 years
following splenectomy in apatient in continuing
first remission, and this 1.3% incidence of fatal
sepsispostsplenectomyis similartothatreported
by Mazza et al in his series of 570 patients.9
During the course of this study we were able to
identify 47 living asplenic patients whose
vaccinationstatuswasunknown,wesubsequently
contacted their general practitioners with a view
to having them appropriately vaccinated against
PneumococcusandHaemophilus influenzaetype
B in accordance with recently published
guidelines.25
Infertilitywasdocumentedineightpatientsduring
the period of hospital follow-up, five of whom
had received MOPP, which has been implicated
as a major cause of gonadal dysfunction;26 in
contrast live births occurred in eight patients
following treatment with combination
chemotherapy (MOPP or LOPP). Fertility status
proved very difficult to assess accurately as
although data on female patients is relatively
easily obtained from the hospital orprimary care
notes, fertility status on male patients is difficult
to determine unless semen analysis following
therapy has been performed. In addition,
pregnancies in the partners of male patients are
not usually recorded in the patients' notes, and
without DNA testing paternity cannot be
confirmed.
In this study we didnotdemonstrate asignificant
improvement in survival in patients treated from
1982-1992, compared to patients treated in the
earlierperiodpriorto 1982, andthishasalsobeen
the finding of the international data base on
Hodgkin's disease,1' so there is still room for
considerableimprovementinlong-termsurvival,
but how will this be achieved? The major factors
identifiedascontributingtomortalityweresepsis,
second malignancy, unresponsive disease, and
disease relapse. The marked reduction in the use
of staging laparotomy should reduce the risk of
death in complete remission by lowering the
incidence ofpost-splenectomy sepsis. The use of
recombinant human granulocyte-colony
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stimulating factor (G-CSF) in selected patients
should reduce the risk of sepsis during the
neutropenic phase following chemotherapy.
Deaths from second malignancies should also
decline with the decreasing use of MOPP type
chemotherapy. Patientswithunresponsivedisease
constitute around 10% in most series, and this
figure must be reduced in order to improve
survival. Most centres are currently using
intensive regimens such as BEAM followed by
autologous stem cell transplant for patients with
refractory and relapsed Hodgkin's disease. For
patients with resistant relapse the results so far
are disappointing, with progression free survival
at five years of only 19.2%27 so perhaps new
chemotherapeutic agents willberequired to alter
CR rates significantly. However a longer period
of follow up is necessary to balance fully the
benefits of intensification with the long term
complications of such treatment.
Results from the IDHD have shown thatpatients
curedfromHodgkin'sdiseasehavearelativerisk
of dying multiplied by 2.09 compared with the
general population,11 and this confirms the need
for long term follow-up studies in order to
accurately document causes of death and alter
treatment protocols to reduce the excess risk of
death in patients cured of their disease. This
study also provides reliable survival data with
follow up on 99.5% oftheoriginal cohort, which
can be compared to the survival of the patients
treated at this centre in the next century, in order
to ascertain ifapparent improvements in therapy
translate into a durable survival advantage.
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